ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nationwide Trends in Medication Use and Adverse Outcomes in Lupus Pregnancies: Progress and Persistent Gaps.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Endometriosis as a comorbidity in pregnant patients with systemic lupus erythematosus: comment on the article by Nguyen et al.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Reply.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Fertility, pregnancy and lactation in women with systemic lupus erythematosus.Nature reviews. Rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003 to 2022.
methodsUsing nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003 to 2022 and matched them to 14,133 non-SLE pregnancies from the general population on maternal age, delivery year, and parity. We assessed proportions of preeclampsia, preterm delivery, and small for gestational age (SGA) birth over time. Antimalarial, glucocorticoid, and low-dose aspirin use were examined during 2007 to 2022. Binomial generalized linear models with an identity link quantified mean annual absolute change (expressed in percentage points [pp]) in APO and treatment proportions.
resultsOverall, SLE pregnancies had 9.1% preeclampsia, 14.7% preterm delivery, and 6.9% SGA births (2003-2022). These outcomes remained stable in the general population but decreased in SLE pregnancies (preeclampsia from 14.1% in 2003-2004 to 9.6% in 2021-2022, -0.11 pp/y; preterm delivery from 25.9% to 11.2%, -0.63 pp/y; and SGA birth from 10.6% to 7.0%, -0.22 pp/y). Declines were more pronounced in nulliparous versus parous SLE pregnancies. APOs modestly decreased over time in SLE pregnancies with antiphospholipid syndrome. Antimalarial use during pregnancy increased from 23.9% in 2007-2008 to 76.5% in 2021-2022 (+3.3 pp/y). Low-dose aspirin use during pregnancy rose from 39.8% to 85.6% (+3.7 pp/y), whereas glucocorticoid use slightly decreased from 43.2% to 40.1% (-0.7 pp/y).
conclusionAPOs in SLE pregnancies have decreased over the past two decades, potentially reflecting improved treatment strategies, particularly increased use of antimalarials and low-dose aspirin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.